{"id":836199,"date":"2026-09-16T19:13:02","date_gmt":"2026-09-16T19:13:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=836199"},"modified":"2026-09-16T19:13:02","modified_gmt":"2026-09-16T19:13:02","slug":"nonhodgkins-lymphoma-pipeline-emerging-therapies-and-key-developments-shaping-the-treatment-landscape-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/nonhodgkins-lymphoma-pipeline-emerging-therapies-and-key-developments-shaping-the-treatment-landscape-delveinsight_836199.html","title":{"rendered":"Non-Hodgkin&#8217;s Lymphoma Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/09\/1789560908.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Non-Hodgkin&#039;s Lymphoma Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/09\/1789560908.jpg\" alt=\"Non-Hodgkin&#039;s Lymphoma Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight\" width=\"225\" height=\"135\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Non-Hodgkin&#8217;s Lymphoma clinical trial analysis report delivers important insights into ongoing research of 180+ pipeline Non-Hodgkin&#8217;s Lymphoma Drugs, clinical strategies, upcoming therapeutics, and commercial analysis.<\/div>\n<p style=\"text-align: justify;\"><strong>(Albany, US) September 16, 2026 &#8211;<\/strong> DelveInsight&rsquo;s, &ldquo;<strong>Non-Hodgkin Lymphoma Pipeline Insights 2026<\/strong>&rdquo; report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Non-Hodgkin Lymphoma pipeline landscape. It covers the Non-Hodgkin&#8217;s Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Hodgkin&#8217;s Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>Dive into DelveInsight&#8217;s comprehensive report today! @<\/strong> <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/non-hodgkins-lymphoma-nhl-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Non-Hodgkin Lymphoma Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>On August 27, 2026, Sichuan Baili Pharmaceutical Co., Ltd<\/strong>. initiated a Phase Ib\/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Tetra-specific Antibody GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin&#8217;s Lymphoma (NHL)<\/li>\n<li>DelveInsight&rsquo;s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 180+ Non-Hodgkin Lymphoma companies working to develop 200+ pipeline therapies for Non-Hodgkin Lymphoma treatment.<\/li>\n<li>The leading <strong>Non-Hodgkin Lymphoma Companies<\/strong> include <strong><em>Bristol Mayer Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA, <\/em><\/strong>and others.<\/li>\n<li>Promising Non-Hodgkin Lymphoma Pipeline Therapies such as <strong><em>Bortezomib + Rituximab, Epcoritamab, Lenalidomide, Ibrutinib, GNC-038, ABT-199, Bendamustine<\/em><\/strong>, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Stay ahead with the most recent pipeline outlook for Non-Hodgkin&rsquo;s Lymphoma @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Non-Hodgkin&rsquo;s Lymphoma Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Non-Hodgkin Lymphoma Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Non-Hodgkin Lymphoma (NHL) encompasses a heterogeneous group of lymphoid malignancies that originate from B lymphocytes, T lymphocytes, or natural killer cells. It is classified into more than 60 distinct subtypes based on cell origin, growth rate, and molecular features. NHL is broadly divided into two categories: indolent (slow-growing) lymphomas, such as follicular lymphoma and marginal zone lymphoma, and aggressive (fast-growing) lymphomas, such as diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma. B-cell lymphomas account for the majority of NHL cases, while T-cell and natural killer cell lymphomas are less common. The presentation of NHL varies based on the subtype and disease stage. Common symptoms include painless lymphadenopathy (swollen lymph nodes) in areas like the neck, armpit, or groin. Systemic &#8220;&#8221;B symptoms,&#8221;&#8221; such as unexplained fever, drenching night sweats, and significant weight loss (&gt;10% of body weight in six months), are often observed in aggressive forms. Other symptoms may include fatigue, abdominal pain or swelling due to lymph node enlargement, and chest pain or shortness of breath if mediastinal nodes are involved. Indolent types may remain asymptomatic for prolonged periods.<\/p>\n<p style=\"text-align: justify;\"><strong>Non-Hodgkin Lymphoma Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Golcadomide: Bristol Myers Squibb<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Golcadomide is a novel cereblon E3 ligase modulator (CELMoD) being investigated for the treatment of aggressive B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). In combination with R-CHOP chemotherapy, it has shown promising antitumor activity in high-risk DLBCL patients, with a high overall response rate (ORR) and complete metabolic response (CMR). Currently, the drug is in Phase III stage of its clinical trial for the treatment of Non-Hodgkin Lymphoma.<strong>&emsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>MEN 1703: Ryvu Therapeutics<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">MEN1703 (SEL24) is a clinical-stage program discovered and developed by Ryvu Therapeutics and licensed to the Menarini Group. MEN1703 is a first-in-class, dual PIM\/FLT3 kinase inhibitor with a unique activity profile. By design, this profile may provide responses to treatment that are more durable than current options and address a disease that has progressed following FLT3 inhibition. Preclinical data suggests therapeutic potential in both hematological malignancies and in solid tumors. Ryvu has granted the Menarini Group an exclusive worldwide license to further research, develop, manufacture and commercialize MEN1703 (SEL24). Currently the drug is in Phase II stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>LP-168: Guangzhou Lupeng Pharmaceutical<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">LP-168 is a third-generation, orally active, irreversible EGFR tyrosine kinase inhibitor (TKI) developed by Guangzhou Lupeng Pharmaceutical for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations, including T790M resistance mutations. It is designed to target mutant EGFR while sparing wild-type EGFR, potentially reducing side effects. LP-168 has shown promising preclinical activity and is currently in clinical trials. The company is exploring its use in both first-line and resistant EGFR-mutant NSCLC settings. Currently the drug is in Phase II stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>DR-0201: Dren Bio<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">DR-0201 is an investigational drug developed by D.R. Pharmatech, designed as a novel anti-cancer agent targeting HER2-expressing tumors, particularly in gastric and breast cancers. It is a HER2-targeting antibody-drug conjugate (ADC) that combines a monoclonal antibody with a cytotoxic payload to selectively kill cancer cells while minimizing damage to healthy tissue. DR-0201 aims to overcome resistance seen with existing HER2 therapies. The product is currently undergoing preclinical or early-phase clinical evaluation. Currently the drug is in Phase I stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>ETR-7072: EntreChem<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">ETR-7072 is an investigational small-molecule drug developed by EntreChem, designed to target cancer by modulating transcriptional programs involved in tumor growth and survival. It is part of EntreChem&rsquo;s novel class of natural product-inspired compounds with multi-targeted activity, potentially affecting epigenetic regulators and oncogenic pathways. ETR-7072 shows promise in preclinical models for treating aggressive and resistant cancers. The compound is currently in early-stage development, with ongoing studies to assess its safety and efficacy. Currently the drug is in Preclinical stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma.<\/p>\n<p style=\"text-align: justify;\"><strong>The Non-Hodgkin&rsquo;s Lymphoma Pipeline Report Provides Insights into<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Non-Hodgkin&rsquo;s Lymphoma with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Hodgkin&rsquo;s Lymphoma Treatment.<\/li>\n<li>Non-Hodgkin&rsquo;s Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Non-Hodgkin&rsquo;s Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Hodgkin&rsquo;s Lymphoma market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Explore groundbreaking therapies and clinical trials in the Non-Hodgkin&rsquo;s Lymphoma Pipeline @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">New Non-Hodgkin&rsquo;s Lymphoma Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Non-Hodgkin&#8217;s Lymphoma Companies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>Bristol Mayer Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA <\/em><\/strong>and others.<\/p>\n<p style=\"text-align: justify;\"><strong>Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Oral<\/li>\n<li>Intramuscular<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Monoclonal antibody<\/li>\n<li>Small molecule<\/li>\n<li>Peptide<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Learn about new pipeline developments with DelveInsight&#8217;s expert analysis @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Non-Hodgkin&rsquo;s Lymphoma Market Drivers and Barriers<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Non-Hodgkin Lymphoma Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<li>Non-Hodgkin Lymphoma Companies- <strong><em>Bristol Mayer Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA <\/em><\/strong>and others.<\/li>\n<li>Non-Hodgkin Lymphoma Pipeline Therapies- <strong><em>Bortezomib + Rituximab, Epcoritamab, Lenalidomide, Ibrutinib, GNC-038, ABT-199, Bendamustine<\/em><\/strong>, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Download DelveInsight&#8217;s in-depth pipeline report today! @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Non-Hodgkin&rsquo;s Lymphoma Companies, Key Products and Unmet Needs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Non-Hodgkin Lymphoma: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Non-Hodgkin Lymphoma&ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Golcadomide: Bristol Myers Squibb<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>MEN 1703: Ryvu Therapeutics<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>DR-0201: Dren Bio<\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>ETR-7072: EntreChem<\/li>\n<li>Inactive Products<\/li>\n<li>Non-Hodgkin Lymphoma Key Companies<\/li>\n<li>Non-Hodgkin Lymphoma Key Products<\/li>\n<li>Non-Hodgkin Lymphoma- Unmet Needs<\/li>\n<li>Non-Hodgkin Lymphoma- Market Drivers and Barriers<\/li>\n<li>Non-Hodgkin Lymphoma- Future Perspectives and Conclusion<\/li>\n<li>Non-Hodgkin Lymphoma Analyst Views<\/li>\n<li>Non-Hodgkin Lymphoma Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=nonhodgkins-lymphoma-pipeline-emerging-therapies-and-key-developments-shaping-the-treatment-landscape-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-hodgkins-lymphoma-nhl-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/non-hodgkins-lymphoma-nhl-pipeline-insight<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=nonhodgkins-lymphoma-pipeline-emerging-therapies-and-key-developments-shaping-the-treatment-landscape-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Non-Hodgkin&#8217;s Lymphoma clinical trial analysis report delivers important insights into ongoing research of 180+ pipeline Non-Hodgkin&#8217;s Lymphoma Drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) September 16, 2026 &#8211; DelveInsight&rsquo;s, &ldquo;Non-Hodgkin Lymphoma Pipeline Insights 2026&rdquo; report provides &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/nonhodgkins-lymphoma-pipeline-emerging-therapies-and-key-developments-shaping-the-treatment-landscape-delveinsight_836199.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,420,413],"tags":[],"class_list":["post-836199","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/836199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=836199"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/836199\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=836199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=836199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=836199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}